BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Jyseleca (filgotinib) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Jyseleca (filgotinib)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06285539-16@assetmemo.bio
DTSTAMP:20261121T005618Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Jyseleca (filgotinib): Phase 2 readout est. (NCT06285539)
DESCRIPTION:Jyseleca (filgotinib)\, phase 2.\nStudy: Drug Rediscovery for R
 are Immune Mediated Inflammatory Diseases\nEstimated primary completion: D
 ecember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/filgoti
 nib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06285539
URL:https://assetmemo.bio/drug/filgotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07554495-16@assetmemo.bio
DTSTAMP:20261121T005618Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Jyseleca (filgotinib): Phase 3 readout est. (NCT07554495)
DESCRIPTION:Jyseleca (filgotinib)\, phase 3.\nStudy: Safety\, Tolerability\
 , Pharmacokinetics\, and Efficacy of Filgotinib for the Treatment of Polya
 rticular-course Juvenile Idiopathic Arthritis in Children and Adolescents\
 nEstimated primary completion: June 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/filgotinib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07554495
URL:https://assetmemo.bio/drug/filgotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06964113-16@assetmemo.bio
DTSTAMP:20261121T005618Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Jyseleca (filgotinib): Phase 4 readout est. (NCT06964113)
DESCRIPTION:Jyseleca (filgotinib)\, phase 4.\nStudy: A Study of Filgotinib 
 200 mg in Korean Participants With Moderately to Severely Active Ulcerativ
 e Colitis Under Routine Clinical Practice\nEstimated primary completion: 3
 0 November 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/filg
 otinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06964113
URL:https://assetmemo.bio/drug/filgotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07553182-16@assetmemo.bio
DTSTAMP:20261121T005618Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Jyseleca (filgotinib): Phase 3 readout est. (NCT07553182)
DESCRIPTION:Jyseleca (filgotinib)\, phase 3.\nStudy: OLE Study With Filgoti
 nib in JIA\nEstimated primary completion: December 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/filgotinib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07553182
URL:https://assetmemo.bio/drug/filgotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06865417-16@assetmemo.bio
DTSTAMP:20261121T005618Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Jyseleca (filgotinib): Phase 3 readout est. (NCT06865417)
DESCRIPTION:Jyseleca (filgotinib)\, phase 3.\nStudy: A Study Evaluating the
  Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis\n
 Estimated primary completion: June 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/filgotinib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06865417
URL:https://assetmemo.bio/drug/filgotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06687551-16@assetmemo.bio
DTSTAMP:20261121T005618Z
DTSTART;VALUE=DATE:20290401
DTEND;VALUE=DATE:20290402
SUMMARY:Jyseleca (filgotinib): Phase 4 readout est. (NCT06687551)
DESCRIPTION:Jyseleca (filgotinib)\, phase 4\, Rheumatoid Arthritis.\nStudy:
  JAK Inhibitor Dose TAPering Strategy Study\nEstimated primary completion:
  1 April 2029. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/filgot
 inib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06687551
URL:https://assetmemo.bio/drug/filgotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07576452-16@assetmemo.bio
DTSTAMP:20261121T005618Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Jyseleca (filgotinib): Phase 4 readout est. (NCT07576452)
DESCRIPTION:Jyseleca (filgotinib)\, phase 4.\nStudy: FirST Lines of Biologi
 cs in pAtients With ulceRaTivE Colitis: a Randomised Controlled Trial\nEst
 imated primary completion: 1 June 2030. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/filgotinib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07576452
URL:https://assetmemo.bio/drug/filgotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
